Mission Therapeutics

Mission Therapeutics Awarded Follow-On Therapeutic Pipeline Program Grant from The Michael J. Fox Foundation

Retrieved on: 
Tuesday, October 12, 2021
Biotechnology, Health, Pharmaceutical, Clinical Trials, Managed Care, Company, Brain, Inflammation, Therapy, NIH Intramural Research Program, Fibrosis, Doctor of Philosophy, Neuroprotection, Drug discovery, Neurodegeneration, Parkinson's disease, The Michael J. Fox Foundation, Goal, Dub, Approximation error, Laboratory, Neuron, MJFF, AbbVie, IP Group, Fox Trial Finder, Mitophagy, Ubiquitin, Familial, Enzyme, Foundation, University, DUB, Kidney disease, Kidney, Awareness, Degenerative disease, DNA, CNS, Volunteering, Disease, Patient, Clinical trial, Research, Government, PD, Sofinnova, Pharmaceutical industry, Mission Therapeutics, The Michael J. Fox Foundation for Parkinson's Research, MISSION THERAPEUTICS, THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH

Mission Therapeutics (Mission), a drug discovery and development company focused on treating mitochondrial diseases, fibrosis and neurodegenerative disorders by selectively inhibiting deubiquitylating enzymes (DUBs), announced today that it has been awarded a Therapeutic Pipeline Program grant of approximately 0.5M USD from The Michael J.

Key Points: 
  • Mission Therapeutics (Mission), a drug discovery and development company focused on treating mitochondrial diseases, fibrosis and neurodegenerative disorders by selectively inhibiting deubiquitylating enzymes (DUBs), announced today that it has been awarded a Therapeutic Pipeline Program grant of approximately 0.5M USD from The Michael J.
  • Fox Foundation is a great accolade, recognizing the importance of USP30 as a potential therapeutic target for PD, and the quality of Missions chemistry.
  • Fox Foundation is dedicated to accelerating a cure for Parkinson's disease and improved therapies for those living with the condition today.
  • In addition to funding $1 billion in research to date, the Foundation has fundamentally altered the trajectory of progress toward a cure.

Mission and AbbVie Collaboration in Alzheimer’s and Parkinson’s Diseases Reaches Next Milestone

Retrieved on: 
Monday, August 9, 2021
Health, Genetics, Research, Pharmaceutical, Science, Biotechnology, AbbVie, Neurodegeneration, Fibrosis, Laboratory, IP Group, Dementia, Kidney disease, Therapy, Sofinnova, Lists of diseases, University, Drug development, DUB, Enzyme, Patient, NYSE, Dub, LinkedIn, Degenerative disease, Neuroscience, Death, Virology, Brain, Research, YouTube, Protein, Drug discovery, Gastroenterology, Instagram, Twitter, Company, Pharmaceutical industry, Mission Therapeutics, AbbVie, MISSION THERAPEUTICS, ABBVIE

In the second major milestone of the Companies research and preclinical development collaboration, AbbVie has nominated two DUB targets to progress to the next stage of drug discovery.

Key Points: 
  • In the second major milestone of the Companies research and preclinical development collaboration, AbbVie has nominated two DUB targets to progress to the next stage of drug discovery.
  • This selection follows supportive data from in vitro and in vivo Alzheimers and Parkinsons disease models.
  • As a result of the nomination, Mission will receive a milestone payment of $20 million from AbbVie.
  • Alzheimers and Parkinsons diseases are the most common neurological disorders worldwide, with over 50 million people living with dementia and Alzheimers disease, and 10 million more with Parkinsons.